Oncology innovations from translational research to the clinic.
Keynotes from leading institutes, Investor panels with active oncology investors, networking & engagement with innovation stakeholders from research, technology transfer & licensing, startup & growth companies, industry & investors worldwide.
SPEAKERS

Michael Salgaller
Supervisor, Invention Development and Marketing Unit (IDMU),Technology Transfer Center, National Cancer Institute

Jeroen Bakker
Principal,
Novo Seeds / Novo Holdings

Melissa McCracken
Principal,
Nextech Invest

Tony Hickson
Chief Business Officer
Cancer Research UK

Kevin Noonan
Partner, Chair of the Biotechnology & Pharmaceuticals Practice Group, MBHB LLP
Prof. Andrew Scott
Research Translation & Commercialisation Lead, Victorian Comprehensive Cancer Centre (VCCC)

Peter Neubeck
Partner,
Kurma Partners

Alejo Chorny
Operating Partner,
Advent France Biotechnology

AGENDA
July 12
10:00 EST
-
Welcome & Opening Remarks
-
Christian J. Suojanen - CEO, Broadreach Global
-
10:05 EST
-
Addressing the Grand Challenges in Cancer Research & Innovation
-
Tony Hickson, Chief Business Officer, Cancer Research UK
-
10:45 EST
-
Selected Company Presentations
July 13
10:00 EST
-
Welcome & Opening
10:15 EST
-
Partnering with the National Cancer Institute
-
Michael Salgaller, Supervisor, Invention Development and Marketing Unit (IDMU),Technology Transfer Center, National Institutes of Health / National Cancer Institute
-
10:45 EST
-
Investor Session I - What are active oncology focused investors looking for? What technologies, approaches & criteria will attract investments?
-
Jeroen Bakker, Principal, Novo Sooeds / Novo Holdings
-
Peter Neubeck, Partner, Kurma Partners
-
Alejo Chorny, Operating Partner, Advent France Biotechnology
-
11:45 EST
-
Selected Company Presentations
July 14
10:00 EST
-
Opportunities in Research Translation in Oncology.
-
Professor Andrew Scott, Research Translation & Commercialisation Lead, Victorian Comprehensive Cancer Centre (VCCC)
-
10:45 EST
-
Protecting Oncology IP in the US - Developments & Strategies
-
Kevin Noonan, Partner, Head of the Biotechnology & Pharmaceutical Practice Group, MBHB LLP
-
11:15 EST
-
Investor Session II - Funding & building companies to transform cancer treatment
-
Melissa McCracken, Principal, Nextech Invest
-
Youssef Bennani, Partner, CTI Life Sciences Fund (tbc)
-
July 15
10:00 EST
-
Roundtable Discussion Panel
10:45 EST
-
Selected Company Presentations